According to research conducted at the Colorado School of Public Health at CU Anschutz, nearly 75% of smokers have low socioeconomic status.
According to the CDC, the smoking rate in the United States has been on the decline over a decade since 2005, and according to research conducted at the Colorado School of Public Health at CU Anschutz, a majority of those who continue to smoke have a low socioeconomic status.
For this study, the authors gathered 2012 data from the national supplement to The Attitudes and Behaviors Surveys (TABS) on Health for adults in the state of Colorado. The authors were particularly interested in establishing smoking prevalence in the state and ascertaining the impact of education, poverty level, occupation, and health insurance status on smoking.
TABS is a population-level survey of Colorado adults to identify and understand influential factors that public health programs can address to improve the health of people in the state. The objective is to document the extent of chronic diseases and health risks and to support planning, implementation, and evaluation of state and local programs to address them.
“In the last half-century, public health efforts helped cut the smoking rate by more than half, but we probably need to change our strategies for helping smokers quit,” said study author Arnold Levinson, PhD, MJ, in a press release.
Their analysis found that smoking ranged between 24.2% to 42.6% among those with a low socioeconomic status. When the analysis combined highest prevalence with low socioeconomic status, prevalence accounted for 31.1% of US adults but only 50% of smokers.
Levinson said that it’s hard to find part of the population experiencing high rates of a health problem and simultaneously representing many affected people. “But with smoking, we have this unusual situation: Americans with lower socioeconomic status today are suffering from epidemic smoking rates, and they make up nearly three-fourths of all our remaining smokers,” he said.
When all the low socioeconomic status categories were combined, it made up about 53% of adults and about 72% of smokers. These are startling data.
Do these numbers represent a difference in smokers' attempts to quit or a need for distinct programs based on the target population? The authors believe that lower socioeconomic smokers who try to quit are less likely to succeed. “The methods that worked for the upper half of society don’t seem to be working well for the other half,” Levinson said.
“Further progress against the US cigarette epidemic depends on focusing tobacco research and program initiatives on reaching and engaging these smokers in cessation strategies that work for them,” the paper concludes.
The study has been published in the Journal of Health Care for the Poor and Undeserved.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More